MA42979A - Anticorps anti-age et procédés d'utilisation correspondants - Google Patents
Anticorps anti-age et procédés d'utilisation correspondantsInfo
- Publication number
- MA42979A MA42979A MA042979A MA42979A MA42979A MA 42979 A MA42979 A MA 42979A MA 042979 A MA042979 A MA 042979A MA 42979 A MA42979 A MA 42979A MA 42979 A MA42979 A MA 42979A
- Authority
- MA
- Morocco
- Prior art keywords
- antibodies
- aging
- related methods
- methods
- aging antibodies
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/44—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4738—Cell cycle regulated proteins, e.g. cyclin, CDC, INK-CCR
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562241007P | 2015-10-13 | 2015-10-13 | |
US14/974,561 US10358502B2 (en) | 2014-12-18 | 2015-12-18 | Product and method for treating sarcopenia |
Publications (1)
Publication Number | Publication Date |
---|---|
MA42979A true MA42979A (fr) | 2021-05-26 |
Family
ID=58518256
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA042979A MA42979A (fr) | 2015-10-13 | 2016-05-27 | Anticorps anti-age et procédés d'utilisation correspondants |
Country Status (12)
Country | Link |
---|---|
EP (1) | EP3362483A1 (fr) |
JP (1) | JP2018535953A (fr) |
KR (1) | KR20180056689A (fr) |
CN (1) | CN108431044A (fr) |
AU (1) | AU2016336959A1 (fr) |
BR (1) | BR112018007422A2 (fr) |
CA (1) | CA3000815C (fr) |
IL (1) | IL258397A (fr) |
MA (1) | MA42979A (fr) |
MX (1) | MX2018004545A (fr) |
RU (1) | RU2766209C2 (fr) |
WO (1) | WO2017065837A1 (fr) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2009143411A2 (fr) | 2008-05-23 | 2009-11-26 | Siwa Corporation | Procédés, compositions et appareil facilitant la régénération |
US9649376B2 (en) | 2010-09-27 | 2017-05-16 | Siwa Corporation | Selective removal of age-modified cells for treatment of atherosclerosis |
US8721571B2 (en) | 2010-11-22 | 2014-05-13 | Siwa Corporation | Selective removal of cells having accumulated agents |
CA2961603C (fr) | 2014-09-19 | 2021-07-13 | Siwa Corporation | Anticorps anti-age pour le traitement de l'inflammation et de troubles auto-immuns |
US10358502B2 (en) | 2014-12-18 | 2019-07-23 | Siwa Corporation | Product and method for treating sarcopenia |
US9993535B2 (en) | 2014-12-18 | 2018-06-12 | Siwa Corporation | Method and composition for treating sarcopenia |
US10889634B2 (en) | 2015-10-13 | 2021-01-12 | Siwa Corporation | Anti-age antibodies and methods of use thereof |
CN109071675A (zh) * | 2016-02-19 | 2018-12-21 | Siwa有限公司 | 使用高级糖化终产物(age)的抗体治疗癌症、杀死转移性癌细胞和预防癌症转移的方法和组合物 |
KR20180133452A (ko) | 2016-04-15 | 2018-12-14 | 시와 코퍼레이션 | 신경퇴행성 질환을 치료하기 위한 항-노화 항체 |
WO2017222535A1 (fr) | 2016-06-23 | 2017-12-28 | Siwa Corporation | Vaccins pour l'utilisation dans le traitement de diverses maladies et troubles |
US10961321B1 (en) | 2017-01-06 | 2021-03-30 | Siwa Corporation | Methods and compositions for treating pain associated with inflammation |
US10925937B1 (en) | 2017-01-06 | 2021-02-23 | Siwa Corporation | Vaccines for use in treating juvenile disorders associated with inflammation |
US10995151B1 (en) | 2017-01-06 | 2021-05-04 | Siwa Corporation | Methods and compositions for treating disease-related cachexia |
US10858449B1 (en) | 2017-01-06 | 2020-12-08 | Siwa Corporation | Methods and compositions for treating osteoarthritis |
JP2020516648A (ja) | 2017-04-13 | 2020-06-11 | シワ コーポレーション | ヒト化モノクローナル終末糖化産物抗体 |
KR20240006702A (ko) * | 2017-05-04 | 2024-01-15 | 시와 코퍼레이션 | 진단용 최종 당화 산물 항체 |
JP6994876B2 (ja) * | 2017-09-05 | 2022-01-14 | 株式会社エッグ | 計測器 |
US11518801B1 (en) | 2017-12-22 | 2022-12-06 | Siwa Corporation | Methods and compositions for treating diabetes and diabetic complications |
WO2019183282A1 (fr) * | 2018-03-21 | 2019-09-26 | Mayo Foundation For Medical Education And Research | Agents sénolytiques pour le traitement de tauopathies |
WO2020023532A1 (fr) * | 2018-07-23 | 2020-01-30 | Siwa Corporation | Méthodes et compositions destinées à traiter les effets chroniques de l'exposition aux rayonnements et aux substances chimiques |
JP2021534144A (ja) * | 2018-08-23 | 2021-12-09 | シワ コーポレーション | Age修飾細胞を除去するための、抗カルボキシメチルリシン抗体及び超音波 |
CN114716551B (zh) * | 2021-11-12 | 2023-01-24 | 深圳市人民医院 | 靶向rage的纳米抗体及其应用 |
WO2023177390A1 (fr) * | 2022-03-14 | 2023-09-21 | Siwa Corporation | Anticorps monoclonal humanisé de produit final de glycation avancée pour le traitement du cancer du pancréas |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4217344A (en) | 1976-06-23 | 1980-08-12 | L'oreal | Compositions containing aqueous dispersions of lipid spheres |
US4911928A (en) | 1987-03-13 | 1990-03-27 | Micro-Pak, Inc. | Paucilamellar lipid vesicles |
US4917951A (en) | 1987-07-28 | 1990-04-17 | Micro-Pak, Inc. | Lipid vesicles formed of surfactants and steroids |
US5624804A (en) * | 1991-12-20 | 1997-04-29 | The Rockefeller University | Immunochemical detection of In vivo advanced glycosylation end products |
US6387373B1 (en) | 1993-01-15 | 2002-05-14 | Novavax, Inc. | Vaccines containing paucilsmellar lipid vesicles as immunological adjuvants |
US6380165B1 (en) | 1997-09-19 | 2002-04-30 | The Picower Institute For Medical Research | Immunological advanced glycation endproduct crosslink |
KR100797308B1 (ko) * | 1999-06-25 | 2008-01-23 | 제넨테크, 인크. | 인간화 항-ErbB2 항체 및 항-ErbB2 항체를 사용한치료 방법 |
JP4012722B2 (ja) * | 2001-11-22 | 2007-11-21 | 株式会社トランスジェニック | カルボキシメチル化ペプチドに対する抗体 |
WO2007098186A2 (fr) | 2006-02-22 | 2007-08-30 | Novavax, Inc. | Compositions d'adjuvant et de vaccin |
WO2009143411A2 (fr) | 2008-05-23 | 2009-11-26 | Siwa Corporation | Procédés, compositions et appareil facilitant la régénération |
-
2016
- 2016-05-27 RU RU2018110885A patent/RU2766209C2/ru active
- 2016-05-27 BR BR112018007422A patent/BR112018007422A2/pt not_active Application Discontinuation
- 2016-05-27 WO PCT/US2016/034880 patent/WO2017065837A1/fr active Application Filing
- 2016-05-27 MA MA042979A patent/MA42979A/fr unknown
- 2016-05-27 EP EP16731696.7A patent/EP3362483A1/fr not_active Withdrawn
- 2016-05-27 MX MX2018004545A patent/MX2018004545A/es unknown
- 2016-05-27 CN CN201680059997.5A patent/CN108431044A/zh active Pending
- 2016-05-27 JP JP2018519727A patent/JP2018535953A/ja active Pending
- 2016-05-27 CA CA3000815A patent/CA3000815C/fr active Active
- 2016-05-27 AU AU2016336959A patent/AU2016336959A1/en not_active Abandoned
- 2016-05-27 KR KR1020187010762A patent/KR20180056689A/ko not_active Application Discontinuation
-
2018
- 2018-03-27 IL IL258397A patent/IL258397A/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2016336959A1 (en) | 2018-04-12 |
CA3000815C (fr) | 2022-11-01 |
RU2018110885A (ru) | 2019-11-19 |
CA3000815A1 (fr) | 2017-04-20 |
RU2018110885A3 (fr) | 2020-01-30 |
EP3362483A1 (fr) | 2018-08-22 |
KR20180056689A (ko) | 2018-05-29 |
IL258397A (en) | 2018-05-31 |
RU2766209C2 (ru) | 2022-02-09 |
BR112018007422A2 (pt) | 2018-10-30 |
JP2018535953A (ja) | 2018-12-06 |
WO2017065837A1 (fr) | 2017-04-20 |
CN108431044A (zh) | 2018-08-21 |
MX2018004545A (es) | 2018-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA42979A (fr) | Anticorps anti-age et procédés d'utilisation correspondants | |
MA43018A (fr) | Anticorps anti-pd1 et procédés d'utilisation | |
FR23C1004I2 (fr) | Antagonistes du fcrn et procédés d'utilisation | |
MA42043A (fr) | Anticorps anti-ox40 et procédés d'utilisation de ceux-ci | |
MA44524A (fr) | Néoantigènes et leurs procédés d'utilisation | |
MA50359A (fr) | Anticorps anti-cd38 et procédés d'utilisation | |
MA53355A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA51552A (fr) | Anticorps anti-ox40 et procédés d'utilisation | |
MA42971A (fr) | Anticorps anti-pdl1, anticorps anti-pld1 activables, et leurs procédés d'utilisation | |
MA46529A (fr) | Anticorps anti-lag-3 et leurs procédés d'utilisation | |
MA47849A (fr) | Anticorps anti-gitr et leurs procédés d'utilisation | |
MA50948A (fr) | Anticorps et procédés d'utilisation de ceux-ci | |
MA42447A (fr) | Anticorps anti-pd-1, anticorps anti-pd-1 activables, et leurs procédés d'utilisation | |
MA43389A (fr) | Anticorps anti-ox40 et leurs procédés d'utilisation | |
MA46290A (fr) | Anticorps contre la protéine régulatrice de signal alpha et procédés d'utilisation | |
MA50949A (fr) | Anticorps anti-ctla-4 et leurs procédés d'utilisation | |
MA42925A (fr) | Anticorps anti-tigit et méthodes d'utilisation | |
MA55097A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA45671A (fr) | Anticorps antivirus zika et procédés d'utilisation | |
MA49950A (fr) | Anticorps anti-b7-h4 et leurs procédés d'utilisation | |
MA41294A (fr) | Anticorps anti-myostatine, polypeptides contenant des variants de régions fc, et procédés d'utilisation | |
MA50956A (fr) | Anticorps anti-cd137 et procédés d'utilisation correspondants | |
MA42446A (fr) | Anticorps spécifiques de la protéine tau hyperphosphorylée et leurs procédés d'utilisation | |
MA46566A (fr) | Oxystérols et leurs procédés d'utilisation | |
MA43365A (fr) | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci |